Vanguard Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,179,600
| Closed | -$711K | – | 4569 |
|
|
2023
Q2 | $711K | Hold |
2,179,600
| – | – | ﹤0.01% | 4010 |
|
|
2023
Q1 | $937K | Hold |
2,179,600
| – | – | ﹤0.01% | 3943 |
|
|
2022
Q4 | $1.16M | Buy |
2,179,600
+1,010
| +0% | +$641 | ﹤0.01% | 3858 |
|
|
2022
Q3 | $1.59M | Buy |
2,178,590
+232,000
| +12% | +$263K | ﹤0.01% | 3846 |
|
|
2022
Q2 | $2.22M | Hold |
1,946,590
| – | – | ﹤0.01% | 3762 |
|
|
2022
Q1 | $3.99M | Buy |
1,946,590
+123,731
| +7% | +$294K | ﹤0.01% | 3635 |
|
|
2021
Q4 | $5.25M | Sell |
1,822,859
-34,391
| -2% | -$127K | ﹤0.01% | 3580 |
|
|
2021
Q3 | $7.88M | Sell |
1,857,250
-18,621
| -1% | -$83.1K | ﹤0.01% | 3382 |
|
|
2021
Q2 | $9.92M | Buy |
1,875,871
+773,343
| +70% | +$3.72M | ﹤0.01% | 3203 |
|
|
2021
Q1 | $5.13M | Buy |
1,102,528
+67,126
| +6% | +$304K | ﹤0.01% | 3515 |
|
|
2020
Q4 | $3.42M | Buy |
1,035,402
+118,833
| +13% | +$451K | ﹤0.01% | 3505 |
|
|
2020
Q3 | $3.03M | Sell |
916,569
-27,555
| -3% | -$101K | ﹤0.01% | 3362 |
|
|
2020
Q2 | $3.18M | Sell |
944,124
-665,093
| -41% | -$3.15M | ﹤0.01% | 3286 |
|
|
2020
Q1 | $6.16M | Sell |
1,609,217
-64,745
| -4% | -$301K | ﹤0.01% | 2860 |
|
|
2019
Q4 | $10.1M | Buy |
1,673,962
+266,603
| +19% | +$1.82M | ﹤0.01% | 2853 |
|
|
2019
Q3 | $10.6M | Buy |
1,407,359
+174,903
| +14% | +$1.97M | ﹤0.01% | 2781 |
|
|
2019
Q2 | $16.7M | Buy |
1,232,456
+691,342
| +128% | +$7.98M | ﹤0.01% | 2601 |
|
|
2019
Q1 | $2.93M | Buy |
541,114
+274,497
| +103% | +$1.34M | ﹤0.01% | 3339 |
|
|
2018
Q4 | $792K | Sell |
266,617
-384,783
| -59% | -$2.11M | ﹤0.01% | 3632 |
|
|
2018
Q3 | $5.32M | Buy |
651,400
+125,327
| +24% | +$962K | ﹤0.01% | 3213 |
|
|
2018
Q2 | $5.12M | Sell |
526,073
-46,621
| -8% | -$478K | ﹤0.01% | 3209 |
|
|
2018
Q1 | $4.98M | Sell |
572,694
-26,457
| -4% | -$285K | ﹤0.01% | 3155 |
|
|
2017
Q4 | $7.5M | Buy |
599,151
+102,346
| +21% | +$1.17M | ﹤0.01% | 2965 |
|
|
2017
Q3 | $4.15M | Buy |
496,805
+18,042
| +4% | +$191K | ﹤0.01% | 3184 |
|
|
2017
Q2 | $8.13M | Buy |
478,763
+52,952
| +12% | +$1.05M | ﹤0.01% | 2870 |
|
|
2017
Q1 | $8.56M | Buy |
425,811
+149,094
| +54% | +$2.96M | ﹤0.01% | 2826 |
|
|
2016
Q4 | $4.31M | Buy |
276,717
+58,924
| +27% | +$794K | ﹤0.01% | 3118 |
|
|
2016
Q3 | $2.84M | Buy |
217,793
+13,578
| +7% | +$129K | ﹤0.01% | 3257 |
|
|
2016
Q2 | $1.4M | Sell |
204,215
-1,896
| -0.9% | -$15.9K | ﹤0.01% | 3504 |
|
|
2016
Q1 | $1.95M | Buy |
206,111
+137,590
| +201% | +$1.11M | ﹤0.01% | 3394 |
|
|
2015
Q4 | $690K | Buy |
68,521
+34,873
| +104% | +$462K | ﹤0.01% | 3737 |
|
|
2015
Q3 | $481K | Buy |
+33,648
| New | +$826K | ﹤0.01% | 3859 |
|
Other funds holding ZYNE
BCM
HCM
YCM
CL
DAM
CM
Vanguard Group's ZYNE Position: Q3 2023 in Review
Vanguard Group sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2023, closing a stake of 2,179,600 shares — an estimated $711K sold.
Vanguard Group first reported a position in ZYNE in Q3 2015 and held it in 32 quarters. The position peaked at $16.7M in Q2 2019. 43 funds tracked by Wall St. Rank hold ZYNE as of Q3 2023.
- Vanguard Group reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
- Vanguard Group sold 2,179,600 Zynerba Pharmaceuticals, Inc shares in Q3 2023, an estimated $711K.
- Vanguard Group first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 32 quarters.
- Vanguard Group's Zynerba Pharmaceuticals, Inc position peaked at $16.7M in Q2 2019.
- 43 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2023.
Based on Vanguard Group's 13F filing for Q3 2023, filed 14 Nov 2023.